相关临床试验
12
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
11
91.7%
终止
1
8.3%
暂无批准数据
- CureVac achieved a dramatic financial turnaround with €371.6 million net income in Q3 2024, reversing from a €54 million operating loss in the same period last year. - The German mRNA company received €400 million upfront from GSK in a restructured partnership that transferred control of COVID-19 and influenza vaccine programs to the British pharmaceutical giant. - CureVac is implementing a 30% workforce reduction and refocusing on oncology, with early clinical data showing antigen-specific T-cell responses in 77% of glioblastoma patients treated with its CVGBM cancer vaccine. - The company's strengthened cash position of €551 million extends its financial runway to 2028, eliminating immediate capital raising requirements.
- SOTIO Biotech has appointed Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer to strengthen its leadership team and advance its pipeline of antibody-drug conjugates and immunotherapies. - Dr. Jensen-Smith has been instrumental in developing SOTIO's lead preclinical ADC candidates SOT106 and SOT109, which target mesenchymal tumors and colorectal cancer respectively. - Dr. Moebius brings over 25 years of experience in drug development and previously served as SOTIO's chief of preclinical development from 2017 to 2024. - The appointments support SOTIO's focus on next-generation ADCs targeting solid tumors and its ongoing Phase 1 VICTORIA-01 study of SOT201 immunocytokine.
- Curatis has disclosed that Corticorelin is the active substance in its C-PTBE-01 therapy for peritumoral brain edema (PTBE), with potential to reduce or eliminate steroid use in treatment. - The company has significantly increased its market size estimates, now projecting over 500,000 PTBE patients globally and a market opportunity exceeding USD 1 billion. - Curatis is targeting an FDA meeting in Q3 2024 to finalize the design of a pivotal Phase 3 trial planned for 2026, while strengthening its team with key appointments in clinical development and technical operations.
- Medigene received FDA clearance for its IND application for MDG1015, a TCR-T therapy targeting NY-ESO-1/LAGE-1a, for advanced solid tumors. - A strategic partnership with WuXi Biologics will co-research TCR-guided T Cell Engagers (TCR-TCEs) for solid tumors, expanding Medigene's pipeline. - Medigene maintains its cash runway guidance into July 2025, supported by a new financing option and ongoing partnerships. - Pre-clinical data for MDG2021, a TCR-T therapy targeting KRAS G12D mutation, were presented at the ESMO Congress 2024.
- Medigene receives FDA clearance for its Investigational New Drug (IND) application for MDG1015, a T-cell receptor engineered T-cell (TCR-T) therapy. - A Phase I clinical trial, EPITOME1015-I, is planned to evaluate MDG1015's safety, feasibility, and preliminary efficacy in patients with advanced solid tumors. - MDG1015 targets NY-ESO-1/LAGE-1a and incorporates a PD1-41BB costimulatory switch protein to enhance anti-tumor activity and persistence. - Medigene anticipates launching the trial by the end of 2024 and expects a data readout from EPITOME1015-I by the end of 2025, pending additional financing.
